Doctor Details

Journals & Publications

1. J Li, JQ Eu, LR Kong, L Wang, YC Lim, BC Goh, A Wong. "Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy" Molecules 2020, 25(20), 4831 (IF 3.27)
2. A Wong, G Bellot, JL Hirpara, S Pervaiz. "Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer' Biochem Pharmacol (2019) DOI: 10.1016/j.bcp.2019.01.020 (IF 4.82)
3. N Ngoi, JQ Eu, JL Hirpara, LZ Wang, JSJ Lim, SC Lee, YC Lim, S Pervaiz, BC Goh, A Wong. 'Targeting Cell Metabolism as Cancer Therapy' Antioxidants and Redox Signaling (2019) DOI 10.1089/ars.2019.7947 (IF 5.83)
4. M Lee, J.L. Hirpara, JQ Eu, G. Sethi, Wang L, B.C. Goh, A Wong. 'Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors'. Redox Biol (2018) DOI: 10.1016/j.redox.2018.101073 (IF 7.6)
5. A Wong, X Xiang, PS Ong, EQY Mitchell, N Syn, I Wee, AP Kumar, WP Yong, G Sethi, BC Goh, P Ho, L Wang. 'A Review on Liquid Chromatography Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.' Pharmaceutics (2018), DOI: 10.3390/pharmaceutics10040221 (IF: 3.9)
6. A Wong, J.L. Hirpara, S. Pervaiz, J.Q. Eu, G. Sethi & B.C. Goh (2017): Do STAT3 inhibitors have potential in the future for cancer therapy?, Expert Opinion on Investigational Drugs, DOI: 10.1080/13543784.2017.1351941 (IF 5.5)
7. A Wong, R Sundar, TT Wang, TC Ng, B Zhang, SH Tan, T Soh, A Pang, CS Tan, S Ow, LZ Wang, J Mogro, J Ho, A Jeyasekharan, Y Huang, CH Thng, CW Chan, M Hartman, P Iau, S Buhari, BC Goh, SC Lee. 'Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer' Oncotarget (2016) DOI: 10.18632/oncotarget.11596 (IF 5.1)
8. A Wong, R Soo, D Tan, SC Lee, J Lim, P Marban, LR Kong, YJ Lee, LZ Wang, WL Thuya, R Soong, MQ Yee, TM Chin, MT Cordero, BR Asuncion, B Pang, S Pervaiz, JL Hirpara, A Sinha, WW Xu, M Yuasa, T Tsunoda, M Motoyama, T Yamauchi, BC Goh, 'Phase I and Biomarker Study of OPB-51602, a Novel Signal Transducer and Activator of Transcription (STAT) 3 Inhibitor, in Patients with Refractory Solid Malignancies'. Annals of Oncology (2015), 26 (5): 998-1005. (IF 11.8)
9. Y Bao, G Oguz, WC Lee, PL Lee, K Ghosh, J Li, P Wang, P Lobie, H Ditzel, A Wong, EY Tan, SC Lee, and Q Yu. "EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy" Nat Comms (2020), 11: 5878 (IF 11.8)
10. V Heong, D Tay, S Goh, B Wee, TZ Tan,R Soo, B Pang, D Lim, A Gopinathan, S Ow, CE Chee, BC Goh, SC Lee, WP Yong, A Wong, R Soong, D Tan 'Whole exome sequencing of multi-regional biopsies from metastatic lesions to evaluate actionable truncal mutations using a single-pass percutaneous technique' Cancers (2020) Article cancers-791356 (IF 6.1)